Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Stauffer, Virginia L., Day, Katie A., Lipsius, Sarah, Wilson, Maria-Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933678/
https://www.ncbi.nlm.nih.gov/pubmed/31881817
http://dx.doi.org/10.1186/s10194-019-1069-x
_version_ 1783483256361975808
author Silberstein, Stephen D.
Stauffer, Virginia L.
Day, Katie A.
Lipsius, Sarah
Wilson, Maria-Carmen
author_facet Silberstein, Stephen D.
Stauffer, Virginia L.
Day, Katie A.
Lipsius, Sarah
Wilson, Maria-Carmen
author_sort Silberstein, Stephen D.
collection PubMed
description
format Online
Article
Text
id pubmed-6933678
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-69336782019-12-30 Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) Silberstein, Stephen D. Stauffer, Virginia L. Day, Katie A. Lipsius, Sarah Wilson, Maria-Carmen J Headache Pain Correction Springer Milan 2019-12-27 /pmc/articles/PMC6933678/ /pubmed/31881817 http://dx.doi.org/10.1186/s10194-019-1069-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Correction
Silberstein, Stephen D.
Stauffer, Virginia L.
Day, Katie A.
Lipsius, Sarah
Wilson, Maria-Carmen
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title_full Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title_fullStr Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title_full_unstemmed Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title_short Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
title_sort correction to: galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (evolve-1 & evolve-2)
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933678/
https://www.ncbi.nlm.nih.gov/pubmed/31881817
http://dx.doi.org/10.1186/s10194-019-1069-x
work_keys_str_mv AT silbersteinstephend correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2
AT stauffervirginial correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2
AT daykatiea correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2
AT lipsiussarah correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2
AT wilsonmariacarmen correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2

Ejemplares similares